ArticleAnnals of hematology2025

TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy.

Seiichiro Katagiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.